Screening-detected colorectal cancers show better long-term survival compared with stage-matched symptomatic cancers

  1. Cienfuegos, Javier A. 123
  2. Baixauli, Jorge 12
  3. Martínez Ortega, Patricia 12
  4. Valentí, Víctor 123
  5. Martínez Regueira, Fernando 12
  6. Martí-Cruchaga, Pablo 12
  7. Zozaya, Gabriel 12
  8. Hernández Lizoain, José Luis 12
  1. 1 Clínica Universitaria de Navarra
    info

    Clínica Universitaria de Navarra

    Pamplona, España

    ROR https://ror.org/03phm3r45

  2. 2 Instituto de Investigación Sanitaria de Navarra
    info

    Instituto de Investigación Sanitaria de Navarra

    Pamplona, España

  3. 3 Instituto de Salud Carlos III
    info

    Instituto de Salud Carlos III

    Madrid, España

    ROR https://ror.org/00ca2c886

Erakutsi afiliazioak +
Aldizkaria:
Revista Española de Enfermedades Digestivas

ISSN: 1130-0108

Argitalpen urtea: 2018

Alea: 110

Zenbakia: 11

Orrialdeak: 684 - 690

Mota: Artikulua

DOI: 10.17235/REED.2018.5509/2018 PMID: 30032629 SCOPUS: 2-s2.0-85056265099 WoS: WOS:000448718900002 DIALNET GOOGLE SCHOLAR lock_openSarbide irekia editor

Beste argitalpen batzuk: Revista Española de Enfermedades Digestivas

Laburpena

Purpose: the aim of this study was to compare overall and disease-free survival among patients with colorectal cancer detected via a screening program as compared to those with symptomatic cancer. Material and methods: patients diagnosed via colonoscopy (screening group) and those with clinical symptoms (non-screening) were identified from 1995 to 2014. Demographic, clinical, surgical and pathologic variables were recorded. Stage I, II and III cancers were included. Overall and disease-free survival were calculated at five and ten years after tumor resection and survival was calculated by matching both groups for cancers at stage I, II and III. Results: two hundred and fifty patients were identified as a result of screening procedures and 1,330 patients presented with symptomatic cancers.There were no significant differences in the baseline characteristics between the two groups. Pathologic stage, degree of differentiation, perineural invasion and lymphovascular invasion were lower in the screening group (p < 0.01). Overall and disease-free survival at five and ten years were higher in the screening group (p < 0.01). However, when the subjects were matched for pathologic stage, significant differences were found between the two groups with regard to stage I and III tumors. Disease-free survival in stage III at five years (79.1 vs 61.7%; p < 0.001) and ten years (79.1% vs 58.5%; p < 0.001) were significantly higher in the screening group. Conclusions: patients with stage I and III tumors that were diagnosed via a screening program have a higher overall and disease-free survival at five and ten years.

Erreferentzia bibliografikoak

  • 10.3322/caac.21387
  • 10.1136/gutjnl-2015-310912
  • 10.1007/s12094-016-1607-9
  • 10.1016/0092-8674(90)90186-I
  • 10.1136/gutjnl-2014-309086
  • 6. Betés M, Muñoz-Navas MA, Duque JM, et al. Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol. 2003;98(12):2648�54.
  • 10.1016/S0140-6736(10)60551-X
  • 10.1002/14651858.CD001216.pub2
  • 10.1007/s10620-015-3600-5
  • 10.1136/bmj.g2467
  • 10.1080/17474124.2017.1264269
  • 10.1056/NEJMoa1108895
  • 10.1056/NEJMcp1512286
  • 10.17235/reed.2017.4569/2016
  • 10.17235/reed.2017.5107/2017
  • 10.1001/jamasurg.2013.8
  • 10.1038/bjc.2014.498
  • 10.1038/bjc.2012.331
  • 19. American Joint Committee on Cancer., editor. Colon and rectum. In: AJCC cancer staging manual. 7th ed. New York, NY; 2010. p. 145�66.
  • 10.1097/00000542-197810000-00001
  • 10.1097/01.sla.0000133083.54934.ae
  • 10.1097/DCR.0b013e3182567e13
  • 10.1002/bjs.1800821249
  • 10.1007/DCR0b013e3181a73e81
  • 25. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity [Internet]. [cited 2017 Mar 22]. Available from: http://www.who.int/vmnis/indicators/haemoglobin.pdf
  • 10.1016/j.surg.2009.10.012
  • 27. Washington MK, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2009;133(10):1539�51.
  • 28. Batsakis JG. Nerves and neurotropic carcinomas. Ann Otol Rhinol Laryngol. 1985;94(4 Pt 1):426�7.
  • 10.1097/PAS.0b013e3181d296ef
  • 30. Hamilton SR, Bosman FT, Boffetta P, et al. Carcinoma of the colon and rectum. In: WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010. p. 134�46.
  • 10.1056/NEJMra040958
  • 10.1007/s12094-010-0586-5
  • 10.1097/DCR.0b013e318274d9c6
  • 10.1093/annonc/mdt354
  • 35. GLOBOCAN Cancer Fact Sheets: colorectal cancers [Internet]. [cited 2018 Jan 9]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/colorectal-new.asp
  • 10.6004/jnccn.2017.0036
  • 10.1111/j.1463-1318.2012.03120.x
  • 10.1016/j.canep.2012.02.006
  • 10.1002/cncr.25613
  • 10.1038/modpathol.2012.61
  • 41. Kay BR, Witte DL. The impact of cancer biology, lead time bias, and length bias in the debate about cancer screening tests. J Insur Med. 1991;23(2):102�4.
  • 10.1093/aje/kwn120
  • 10.1016/j.critrevonc.2012.08.006
  • 10.1056/NEJMe0806029
  • 10.1136/jech.2003.008466
  • 46. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane database Syst Rev. 2006;(1)(1):CD005033.
  • 10.1038/nrclinonc.2014.224
  • 10.1097/SLA.0b013e31821fd469